皮下注射曲妥珠单抗用于人表皮生长因子受体2阳性早期乳腺癌辅助治疗的安全性与耐受性:SafeHer III期研究2573例患者的主要分析
SafeHer III期研究评估皮下注射曲妥珠单抗(H SC)600 mg固定剂量每3周1次共18周期辅助治疗HER2阳性I-IIIC期早期乳腺癌的安全性。2573例中88.7%发生不良事件,5.0%因不良事件停药,23.2%发生≥3级不良事件,12.7%发生严重不良事件,≥3级心脏疾病0.9%。结论认为该方案安全可耐受,与静脉和皮下曲妥珠单抗已知安全性一致。
要点
- 2573例中88.7%发生不良事件,5.0%因不良事件停药,23.2%发生≥3级不良事件。
- ≥3级心脏疾病24例(0.9%),充血性心力衰竭8例(0.3%)。
- 不良事件发生率随化疗时序变化,同步化疗亚组高于序贯化疗亚组。
核心结论
- SafeHer研究证实皮下注射曲妥珠单抗600 mg固定剂量每3周1次共18周期、联合同步或序贯化疗辅助治疗HER2阳性早期乳腺癌安全可耐受,主要分析结果与静脉及皮下曲妥珠单抗已知安全性一致。
研究设计与样本
- III期SafeHer研究(NCT01566721),评估皮下注射曲妥珠单抗(Herceptin® SC)经手持注射器(A队列)或一次性注射装置(B队列)给药、联合或不联合化疗辅助治疗HER2阳性I-IIIC期早期乳腺癌的安全性。
- 患者接受600 mg固定剂量皮下注射曲妥珠单抗每3周1次共18周期,化疗方案由研究者决定,皮下曲妥珠单抗单药治疗限于不超过10%的人群。
- 分析数据从首次皮下注射曲妥珠单抗给药至末次给药后28天(加5天窗口),结果为描述性分析,共2573例患者。
主要发现
- 总体人群中2282/2573例(88.7%)发生不良事件。
- 128例(5.0%)发生导致研究药物停药的不良事件;596例(23.2%)发生≥3级不良事件;326例(12.7%)发生严重不良事件。
- ≥3级心脏疾病报告于24例(0.9%),包括充血性心力衰竭8例(0.3%)。
- 两个队列中不良事件发生率均随化疗时序变化,同步化疗亚组高于序贯化疗亚组;同步化疗亚组中,实际同步化疗期间的不良事件较未接受同步化疗期间更常见。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To assess the safety and tolerability of adjuvant subcutaneous trastuzumab (Herceptin® SC, H SC), delivered from an H SC Vial via hand-held syringe (Cohort A) or single-use injection device (Cohort B), with or without chemotherapy, for human epidermal growth factor receptor 2 (HER2)-positive stage I to IIIC early breast cancer (EBC) in the phase III SafeHer study (NCT01566721). METHODS: Patients received 600 mg fixed-dose H SC every 3 weeks for 18 cycles. The chemotherapy partner was at the investigators' discretion (H SC monotherapy was limited to ≤10% of the population). Data from the first H SC dose until 28 days (plus a 5-day window) after the last dose are presented. Results are descriptive. RESULTS: In the overall population, 2282/2573 patients (88.7%) experienced adverse events (AEs). Of the above, 128 (5.0%) patients experienced AEs leading to study drug discontinuation; 596 (23.2%) experienced grade ≥ 3 AEs and 326 (12.7%) experienced serious AEs. Grade ≥ 3 cardiac disorders were reported in 24 patients (0.9%), including congestive heart failure in eight (0.3%). As expected, the AE rates varied according to the timing of chemotherapy in both cohorts, with higher rates in concurrent versus sequential chemotherapy subgroups. In the concurrent chemotherapy subgroup, AEs were more common during the actual period of concurrent chemotherapy compared with the period when patients did not receive concurrent chemotherapy. CONCLUSION: SafeHer confirms the safety and tolerability of the H SC 600 mg fixed dose for 1 year (every 3 weeks for 18 cycles) as adjuvant therapy with concurrent or sequential chemotherapy for HER2-positive EBC. These primary analysis results are consistent with the known safety profile for intravenous H and H SC.
引用
- Gligorov J, Ataseven B, Verrill M, et al. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. Eur J Cancer. 2017. PMID: 28625777. doi:10.1016/j.ejca.2017.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。